Genmab A/S
GMAB
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivaā¦ read more
Healthcare
Biotechnology
16 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$23.31
Price+1.44%
$0.33
1Y
Price
Market Cap
$14.709b
Large
Price/Earnings 3y Avg5y Avg
12.1x
Premium
Premium
Financials Overview
Key metrics over the past few years+5.4%
EBITDA Margin+4.0%
Net Profit Margin+5.2%
Free Cash Flow MarginRevenue
$22.316b
+3.7%
1y CAGR+15.7%
3y CAGR+29.8%
5y CAGREarnings
$6.714b
-14.4%
1y CAGR+15.2%
3y CAGR+32.5%
5y CAGREPS
$10.42
-14.2%
1y CAGR+16.6%
3y CAGR+33.5%
5y CAGRBook Value
$5.296b
$6.586b
Assets$1.290b
Liabilities$143m
DebtDebt to Assets
2.2%
-
Debt to EBITDAFree Cash Flow
$6.346b
-16.3%
1y CAGR+28.9%
3y CAGR+42.2%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in DKK.No items found.
Press Releases
Statements and updates from the company